SYNLOGIC, INC. [SYBX] - / Caldera Therapeutics merger
Synlogic, Inc. will merge with Caldera Therapeutics, Inc. as part of a tax-free reorganization, with Synlogic surviving as a wholly owned subsidiary of Sonic Holdco, Inc.
Why this matters
Synlogic, Inc., a pharmaceutical company focused on developing synthetic biotic medicines, is set to merge with Caldera Therapeutics, Inc. in a tax-free reorganization. The merger will result in Synlogic becoming a wholly owned subsidiary of Sonic Holdco, Inc. This strategic move is aimed at advancing Caldera's innovative program, particularly the development of CLD-423, a bispecific antibody targeting inflammatory bowel disease and other immune-mediated diseases. The merger is contingent upon Caldera receiving at least $278 million under a Securities Purchase Agreement and Synlogic obtaining necessary stockholder approval.